Biocon opens book for Syngene IPO
Indian pharma company spins off contract research arm, hoping markets will regain a solid footing after Monday's sharp fall.
July 27, 2015
Indian pharma company Biocon has begun pre-marketing an initial public offering of its clinical research arm, Syngene, with a target fundraising of $100 million to $150 million.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].